sun pharma advanced research share price target 2025 | Stock Forecast

 share price target

Hello! This article is about sun pharma advanced research share price target for 2025, 2026, 2030 . We'll talk about how the company makes money, areas where it might grow, and other important info. After reviewing the stock, we'll share the results with you. sun pharma advanced research seems like a good long-term investment, and we'll cover its basics, analysis, and more to help you decide. Let's start by looking at the company's history and business structure.

Industry - Pharmaceuticals

Market Cap (as of Jan 4, 2024) - ₹17,214 Cr

Revenue (FY 2023) - ₹559.14 Cr

Shareholding Pattern

1. Promoters 65.67%
2. Foreign Institutional Investors (FII) 7.24%
3. Domestic Institutional Investors (DII) 13.84%
4. Retail Investors 13.25%

Last 5 Years' Financial Performance

Year	Sales (Cr)	Net Profit (Cr)	EPS (₹)
FY 2023	559.14	55.59	8.51
FY 2022	380.48	51.5	7.91
FY 2021	255.4	40.8	6.26
FY 2020	151.2	15.07	2.31
FY 2019	124.7	10.54	1.6

Positive Signs

1. Strong revenue growth: 45.94% CAGR for past 3 years.
2. Healthy financials: Debt-free with strong cash flow.
3. High promoter holding: Indicates long-term commitment.
4. Strong parent company: Sun Pharma provides support and resources.
5. Growing pharmaceutical market: Promising industry outlook.

Negative Signs

1. Profitability fluctuations: Net profit dipped in FY 2023 despite strong revenue.
2. Limited product portfolio: Concentrated on few niche segments.
3. Dependence on parent company: Future success linked to Sun Pharma's performance.
4. Volatile stock price: High Beta implies higher risk compared to market.

Operations & Earnings

• SPARC develops and licenses novel drug delivery systems and formulations.
• Earns profits through licensing agreements, royalty income, and collaborations.
• Focuses on areas like oral controlled-release, transdermal patches, and injectables.

Technical Analysis

• Moving averages: The stock price is currently above all of the 50-day, 100-day, and 200-day moving averages, which is a bullish signal.
• Relative Strength Index (RSI): The RSI is a technical indicator that measures the momentum of a stock price. The RSI for SPARC is currently around 66, which is above the neutral level of 50 but below the overbought level of 70. This suggests that the stock is still in a healthy uptrend, but it may be due for a pullback in the short term.

Fundamental Analysis

• Company financials: Sun Pharma Advanced Research is a subsidiary of Sun Pharmaceutical Industries Ltd, a leading Indian pharmaceutical company. The company's financials are strong, with revenue and profits growing in recent years.
• Industry outlook: The Indian pharmaceutical industry is expected to grow at a healthy rate in the coming years, driven by factors such as an aging population, rising disposable incomes, and increasing government spending on healthcare.
• Overall market conditions: The Indian stock market has been performing well in recent months, and this has helped to boost the share price of SPARC.
• Overall, the analysis suggests that Sun Pharma Advanced Research is a stock with good long-term prospects. However, the stock may be due for a pullback in the short term, so investors should be cautious.

sun pharma advanced research share price Target 2025

For 2025, the stock price target for Sun Pharma Advanced Research Company Ltd is estimated to be ₹419.3 at the lowest and ₹440.3 at the highest. This estimate is based on the Discounted Cash Flow (DCF) method, which uses projected future cash flows.

Keep in mind that DCF results are estimates based on assumptions. It's important to consider various scenarios, sensitivity analysis, and other valuation methods to fully understand Sun Pharma Advanced Research Company Ltd's potential value.

DISCLAIMER: Dear readers, we’d like to inform you that we are not authorized by SEBI (Securities and Exchange Board of India). The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. Also, the share price predictions are completely for reference purposes. The price predictions will only be valid when there are positive signs on the market. Any uncertainty about the company’s future or the current state of the market will not be considered in this study. Though this is just for informational purposes, We are not responsible for any financial loss you might incur through the information on this site. We are here to provide timely updates about the stock market and financial products to help you make better investment choices. Do your own research before any investment.